» Articles » PMID: 39400264

DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies

Abstract

Purpose: DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the goals of the Registry is to continue to refine these guidelines as additional data become available.

Experimental Design: Individuals were enrolled in the International PPB/DICER1 Registry, the International Ovarian and Testicular Stromal Tumor Registry, and/or the NCI Natural History of DICER1 Syndrome study.

Results: Review of participant records identified 713 participants with a germline DICER1 P/LP variant from 38 countries. To date, 5 cases of type I and 29 cases of type Ir PPB have been diagnosed by surveillance in enrolled individuals. One hundred and three individuals with a germline P/LP variant developed a primary ovarian Sertoli-Leydig cell tumor at a median age of 14 years (range: 11 months-66 years); 13% were diagnosed before 8 years of age, the current age of onset of pelvic surveillance. Additionally, 4% of Sertoli-Leydig cell tumors were diagnosed before 4 years of age.

Conclusions: Ongoing data collection highlights the role of lung surveillance in the early detection of PPB and suggests that imaging-based detection and early resection may decrease the risk of advanced PPB. DICER1-related ovarian tumors were detected before 8 years of age, prompting the Registry to recommend earlier initiation of ovarian surveillance with pelvic ultrasound beginning at the time of detection of a germline DICER1 P/LP variant.

Citing Articles

DICER1: The Argonaute Endonuclease Family Member and Its Role in Pediatric and Youth Pathology.

Sergi C, Minervini F Biology (Basel). 2025; 14(1).

PMID: 39857323 PMC: 11761906. DOI: 10.3390/biology14010093.


Pleuropulmonary blastoma and DICER1-related tumor predisposition: from clinicopathologic observations to clinical trial.

Nelson A, Chen K, Schultz K Curr Opin Pediatr. 2024; 37(1):48-55.

PMID: 39699100 PMC: 11661683. DOI: 10.1097/MOP.0000000000001431.


Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex.

Schultz K, MacFarland S, Perrino M, Mitchell S, Kamihara J, Nelson A Clin Cancer Res. 2024; 31(2):234-244.

PMID: 39540884 PMC: 11747828. DOI: 10.1158/1078-0432.CCR-24-1947.

References
1.
Canberk S, Ferreira J, Pereira L, Batista R, Vieira A, Soares P . Analyzing the Role of DICER1 Germline Variations in Papillary Thyroid Carcinoma. Eur Thyroid J. 2021; 9(6):296-303. PMC: 7923931. DOI: 10.1159/000509183. View

2.
Gonzalez I, Stewart D, Schultz K, Field A, Hill D, Dehner L . DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma. Mod Pathol. 2021; 35(1):4-22. PMC: 8695383. DOI: 10.1038/s41379-021-00905-8. View

3.
Priest J, Williams G, Manera R, Jenkinson H, Brundler M, Davis S . Ciliary body medulloepithelioma: four cases associated with pleuropulmonary blastoma--a report from the International Pleuropulmonary Blastoma Registry. Br J Ophthalmol. 2010; 95(7):1001-5. DOI: 10.1136/bjo.2010.189779. View

4.
Kim J, Haley J, Hatton J, Mirshahi U, Rao H, Ramos M . A genome-first approach to characterize DICER1 pathogenic variant prevalence, penetrance and cancer, thyroid, and other phenotypes in 2 population-scale cohorts. Genet Med Open. 2024; 2. PMC: 11271802. DOI: 10.1016/j.gimo.2024.101846. View

5.
de Kock L, Sabbaghian N, Plourde F, Srivastava A, Weber E, Bouron-Dal Soglio D . Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol. 2014; 128(1):111-22. PMC: 4129448. DOI: 10.1007/s00401-014-1285-z. View